medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2017, Number 4

<< Back Next >>

Ann Hepatol 2017; 16 (4)

Prevalence, Risk Factors, and Survival of Patients with Intrahepatic Cholangiocarcinoma

Chinchilla-López P, Aguilar-Olivos NE, García-Gómez J, Hernández-Alejandro KK, Chablé-Montero F, Motola-Kuba D, Patel T, Méndez-Sánchez N

Language: English
References: 22
Page: 565-568
PDF size: 123.92 Kb.


ABSTRACT

Purpose. To investigate the prevalence, related risk factors, and survival of intrahepatic cholangiocarcinoma in a Mexican population. Material and methods. We conducted a cross-sectional study at Medica Sur Hospital in Mexico City with approval of the local research ethics committee. We found cases by reviewing all clinical records of in-patients between October 2005 and January 2016 who had been diagnosed with malignant liver tumors. Clinical characteristics and comorbidities were obtained to evaluate the probable risk factors and the Charlson index. The cases were staged based on the TNM staging system for bile duct tumors used by the American Joint Committee on Cancer and median patient survival rates were calculated using the Kaplan-Meier method. Results. We reviewed 233 cases of hepatic cancer. Amongst these, hepatocellular carcinomas represented 19.3% (n = 45), followed by intrahepatic cholangiocarcinomas, which accounted for 7.7% (n = 18). The median age of patients with intrahepatic cholangiocarcinoma was 63 years, and most of them presented with cholestasis and intrahepatic biliary ductal dilation. Unfortunately, 89% (n = 16) of them were in an advanced stage and 80% had multicentric tumors. Median survival was 286 days among patients with advanced stage tumors (25th-75th interquartile range, 174-645 days). No correlation was found between the presence of comorbidities defined by the Charlson index, and survival. We evaluated the presence of definite and probable risk factors for the development of intrahepatic cholangiocarcinoma, that is, smoking, alcohol consumption, and primary sclerosing cholangitis. Discussion. We found an overall prevalence of intrahepatic cholangiocarcinoma of 7.7%; unfortunately, these patients were diagnosed at advanced stages. Smoking and primary sclerosing cholangitis were the positive risk factors for its development in this population.


REFERENCES

  1. Endo I, Gonen M, Yopp AC, Dalal KM, Zhou Q, Klimstra D, D'Angelica M, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg 2008; 1: 84-96.

  2. Khan SA, Thomas HC, Davidson BR, Taylor SD. Cholangiocarcinoma. Lancet 2005; 9493: 1303-14.

  3. Morise Z, Sugioka A, Tokoro T, Tanahashi Y, Okabe Y, Kagawa T, Takeura C. Surgery and chemotherapy for intrahepatic cholangiocarcinoma. World J Hepatol 2010; 2: 58-64.

  4. Doherty B, Nambudiri VE, Palmer WC. Update on the Diagnosis and Treatment of Cholangiocarcinoma. Curr Gastroenterol Rep 2017; 1: 2.

  5. Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2002; 2: 10.

  6. Khan SA, Taylor SD, Toledano MB, Beck A, Elliot P, Thomas HC. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol 2002; 6: 806-13.

  7. McGlynn KA, Tarone RE, El-Serag HB. A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States. Cancer Epidemiol Biomarkers Prev 2006; 6: 1198-203.

  8. Shaib YH, Davila JA, McGlynn K, El-Serag HB. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol 2004; 3: 472-7.

  9. Shaib YH, Davila JA, Henderson L, McGlynn KA, El-Serag HB. Endoscopic and surgical therapy for intrahepatic cholangiocarcinoma in the United States: a population- based study. J Clin Gastroenterol 2007; 10: 911-7.

  10. El-Serag HB, Engels EA, Landgren O, Chiao E, Henderson L, Amaratunge HC, Giordano TP. Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population- based study of U.S. veterans. Hepatology 2009; 1: 116-23.

  11. Ustundag Y, Bayraktar Y. Cholangiocarcinoma: a compact review of the literature. World J Gastroenterol 2008; 42: 6458-66.

  12. Ronnekleiv SM, Pawlik TM. Stating of intrahepatic cholangiocarcinoma. Hepatobil Surg Nutr 2017; 1: 35-43.

  13. Sirica AE, Dumur CI, Campbell DJ, Almenara JA, Ogunwobi OO, Dewitt JL.Intrahepatic cholangiocarcinoma progression: prognostic factors and basic mechanisms. Clinical Gastroenteroly and Hepatology: the official clinical practice Journal of the American Gastroenterology Association 2009; 11: S68-78.

  14. Khan SA, Emadossadaty S, Ladep NG, Thomas HC, Elliott P, Taylor-Robinson SD, Toledano MB. Rising trends in cholangiocarcinoma: is the ICD classification system misleading us? J Hepatol 2012; 4: 848-54.

  15. McLean L, Pate T. Racial and ethnic variation in the epidemiology of intrahepatic cholangiocarcinoma in the United States. Liver International: official journal of the International Association for the study of the liver 2006; 9: 1047-53.

  16. Razumilava N, Gores G. Cholangiocarcinoma. Lancet 2014; 9935: 2168-79.

  17. Shaib Y, El-Serag HB. The Epidemiology of cholangiocarcinoma. Seminars in Liver Disease 2004; 2: 115-25.

  18. Bridgewater J, Galle PR, Khan SA, Llovet JM, Park JW, Patel T, Pawlik TM, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol 2014; 6: 1268-89.

  19. Yuan L, Luo X, Lu X, Huang B, Cai Q. Liver resection for intrahepatic cholangiocarcinoma in AJCC stage: An evaluation of the survival benefit and prognostic accuracy of current AJCC stating sustem on N and M classification. Oncology Reports 2016; 5: 2663-72.

  20. Benito del Valle M, Muller T, Bjornsson E, Otten M, Volkmann M, Guckelberger O, Wiedenmann B, et al. The impact of elevated serum IgG4 levels in patients with primary sclerosing cholangitis. Dig Liver Dis: official journal of the Italian Society of Gastroenteroly and de Italian Association for the study of the Liver 2014; 10: 903-8.

  21. Welzel TM, Graubard BI, El-Serag HB, Shaib YH, Hsing AW, Davila JA, McGlynn KA. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population- based case-control study. Clin Gastroenterol Hepatol: the official clinical practice journal of the American Gastroenterological Association 2007; 10: 1221-8.

  22. Shin HR, Oh JK, Masuyer E, Curado MP, Bouvard V, Fang YY, Wiangnon S, et al. Epidemiology of cholangiocarcinoma: an update focusing on risk factors. Cancer Science 2010; 3: 579-85.




2020     |     www.medigraphic.com